Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma.

Tekijä Seto, M, Jaeger, U, Hockett, R D, Graninger, W, Bennett, S, Goldman, P, Korsmeyer, S J
Julkaistu 1988

BTK inhibition is a potent approach to block IgE‐mediated histamine release in human basophils

Tekijä Smiljkovic, D., Blatt, K., Stefanzl, G., Dorofeeva, Y., Skrabs, C., Focke‐Tejkl, M., Sperr, W. R., Jaeger, U., Valenta, R., Valent, P.
Julkaisussa Allergy (2017)

Consensus statement on the use of rituximab in patients with rheumatoid arthritis

Tekijä Smolen, J S, Keystone, E C, Emery, P, Breedveld, F C, Betteridge, N, Burmester, G R, Dougados, M, Ferraccioli, G, Jaeger, U, Klareskog, L, Kvien, T K, Martin‐Mola, E, Pavelka, K
Julkaistu 2007

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

Tekijä Maurer, M J, Habermann, T M, Shi, Q, Schmitz, N, Cunningham, D, Pfreundschuh, M, Seymour, J F, Jaeger, U, Haioun, C, Tilly, H, Ghesquieres, H, Merli, F, Ziepert, M, Herbrecht, R, Flament, J, Fu, T, Flowers, C R, Coiffier, B
Julkaisussa Ann Oncol (2018)

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib

Tekijä Kazianka, L, Drucker, C, Skrabs, C, Thomas, W, Melchardt, T, Struve, S, Bergmann, M, Staber, P B, Porpaczy, E, Einberger, C, Heinz, M, Hauswirth, A, Raderer, M, Pabinger, I, Thalhammer, R, Egle, A, Wendtner, C-M, Follows, G, Hoermann, G, Quehenberger, P, Jilma, B, Jaeger, U
Julkaisussa Leukemia (2017)

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

Tekijä Brown, J R, Hillmen, P, O’Brien, S, Barrientos, J C, Reddy, N M, Coutre, S E, Tam, C S, Mulligan, S P, Jaeger, U, Barr, P M, Furman, R R, Kipps, T J, Cymbalista, F, Thornton, P, Caligaris-Cappio, F, Delgado, J, Montillo, M, DeVos, S, Moreno, C, Pagel, J M, Munir, T, Burger, J A, Chung, D, Lin, J, Gau, L, Chang, B, Cole, G, Hsu, E, James, D F, Byrd, J C
Julkaisussa Leukemia (2018)

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

Tekijä Byrd, J.C., Brown, J.R., O’Brien, S., Barrientos, J.C., Kay, N.E., Reddy, N.M., Coutre, S., Tam, C.S., Mulligan, S.P., Jaeger, U., Devereux, S., Barr, P.M., Furman, R.R., Kipps, T.J., Cymbalista, F., Pocock, C., Thornton, P., Caligaris-Cappio, F., Robak, T., Delgado, J., Schuster, S.J., Montillo, M., Schuh, A., de Vos, S., Gill, D., Bloor, A., Dearden, C., Moreno, C., Jones, J.J., Chu, A.D., Fardis, M., McGreivy, J., Clow, F., James, D.F., Hillmen, P.
Julkaistu 2014